Variable | n (frequency) |
---|---|
Age (years) | |
Median | 54.5 (19–85) |
< 50 | 37 (37%) |
> 50 | 63 (63%) |
Gender | |
Male | 51 (51%) |
Female | 49 (49%) |
Laterality | |
Right | 30 (30%) |
Left | 70 (70%) |
Lymphovascular invasion | |
Present | 27 (27%) |
Absent | 73 (73%) |
T stage | |
T1 | 1 (1%) |
T2 | 7 (7%) |
T3 | 81 (81%) |
T4 | 11 (11%) |
N stage | |
N0 | 32 (32%) |
N1 | 30 (30%) |
N2a | 19 (19%) |
N2b | 19 (19%) |
Tumor grade | |
Well differentiated | 3 (3%) |
Moderately differentiated | 74 (74%) |
Poorly differentiated | 23 (23%) |
Tumor type | |
Adenoarcinoma, NOS | 79 (79%) |
Mucinous | 13 (13%) |
Medullary | 2 (2%) |
Signet ring | 5 (5%) |
Perinodal spread | |
Present | 47 (47%) |
Absent | 53 (53%) |
Mucinous histology (%) | |
Absent | 68 (68%) |
< 10 | 12 (12%) |
10–50 | 7 (7%) |
> 50 | 13 (13%) |
Signet ring differentiation | |
Present | 16 (16%) |
Absent | 84 (84%) |
Medullary differentiation | |
Present | 2 (2%) |
Absent | 98 (98%) |
Necrosis | |
Absent | 6 (6%) |
Focal | 70 (70%) |
Widespread | 24 (24%) |
Tumor infiltrating lymphocytes | |
None | 57 (57%) |
Mild to moderate | 25 (25%) |
Marked | 18 (18%) |
Peri-tumoral lymphocytic response | |
None | 67 (67%) |
Mild to moderate | 18 (18%) |
Marked | 15 (15%) |
Pre-existing polyp | |
Present | 10 (10%) |
Absent | 90 (90%) |